BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36765483)

  • 21. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
    Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
    Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
    Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
    Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8
    Xu Y; Liu Z; Lv L; Li P; Xiu B; Qian W; Liang A
    J Exp Clin Cancer Res; 2020 Nov; 39(1):238. PubMed ID: 33168024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
    Wang WG; Jiang XN; Sheng D; Sun CB; Lee J; Zhou XY; Li XQ
    Lab Invest; 2019 Oct; 99(10):1418-1427. PubMed ID: 31197205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-374b increases the CIK expression and mediates biological function changes in cervical cancer cells by targeting the PD-1/PD-L1 signaling pathway.
    Wang C; Kuang L; Han L
    J Reprod Immunol; 2021 Feb; 143():103265. PubMed ID: 33360511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma.
    Atwa SM; Handoussa H; Hosny KM; Odenthal M; El Tayebi HM
    World J Hepatol; 2020 Dec; 12(12):1211-1227. PubMed ID: 33442449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
    Huang J; Weng Q; Shi Y; Mao W; Zhao Z; Wu R; Ren J; Fang S; Lu C; Du Y; Ji J
    FEBS Open Bio; 2020 Jun; 10(6):1065-1071. PubMed ID: 32237066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
    Zhang N; Fan J; Deng Z
    Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a.
    Zhang J; Chou X; Zhuang M; Zhu C; Hu Y; Cheng D; Liu Z
    J Cell Biochem; 2020 Oct; 121(10):4188-4195. PubMed ID: 31898338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint.
    Zheng W; Lai G; Lin Q; Issah MA; Fu H; Shen J
    Front Cell Dev Biol; 2021; 9():735855. PubMed ID: 34778251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
    Fang X; Xiu B; Yang Z; Qiu W; Zhang L; Zhang S; Wu Y; Zhu X; Chen X; Xie S; Yi X; Liang A; Zeng Y
    Medicine (Baltimore); 2017 Apr; 96(15):e6398. PubMed ID: 28403071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.
    Lin J; Qiu Y; Zheng X; Dai Y; Xu T
    BMC Cancer; 2022 Jul; 22(1):756. PubMed ID: 35818041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
    Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
    J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
    Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
    Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
    Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
    Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.